Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

22.07 -0.95 (-4.13%)

Streaming Delayed Price Updated: 4:00 PM EST, Mar 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,722,117
Open	22.40
Bid (Size)	21.42 (300)
Ask (Size)	23.00 (100)
Prev. Close	23.02
Today's Range	21.88 - 22.88
52wk Range	18.41 - 43.22
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

Today 13:44 EST

From Pomerantz LLP

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

Today 9:47 EST

From Schall Law

Via GlobeNewswire

Performance

YTD	-6.5%	-6.5%
1 Month	-10.9%	-10.9%
3 Month	-33.9%	-33.9%
6 Month	-31.1%	-31.1%
1 Year	-46.5%	-46.5%

More News

NASDAQ: RARE INVESTOR ALERT: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors of an April 6, 2026 Deadline

March 02, 2026

From Berger Montague

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

March 01, 2026

Via NewMediaWire

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

March 01, 2026

Via TheNewswire.com

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm

February 28, 2026

Via NewMediaWire

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm

February 28, 2026

Via TheNewswire.com

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm

February 27, 2026

Via NewMediaWire

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors With Losses to Contact the Firm

February 27, 2026

Via TheNewswire.com

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

February 25, 2026

From SkyMedia, LLC

Via GlobeNewswire

RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026

February 25, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

February 25, 2026

Via TheNewswire.com

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

February 25, 2026

Via NewMediaWire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

February 24, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

February 24, 2026

From Pomerantz LLP

Via GlobeNewswire

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 24, 2026

From Schall Law

Via GlobeNewswire

Ultragenyx to Participate at Investor Conferences in March

February 23, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit

February 23, 2026

Via NewMediaWire

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Deadline in Securities Fraud Class Action Lawsuit

February 23, 2026

Via TheNewswire.com

RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗

February 23, 2026

Via Stocktwits

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

February 23, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline

February 22, 2026

Via TheNewswire.com

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud Class Action Lawsuit Filed; April 6, 2026, Lead Plaintiff Deadline

February 22, 2026

Via NewMediaWire

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline

February 21, 2026

Via TheNewswire.com

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline

February 21, 2026

Via NewMediaWire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 22.07

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 03/03/26 04:00 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.56B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.